Cytodyn Inc (CYDY)

[CTMedic]

Don

You quoted:

leronlimab did have exclusions in their trial for patients who were too sick:

https://clinicaltrials.gov/ct2/show/NCT04347239
None of the following: Respiratory failure (defined by endotracheal intubation and mechanical ventilation, oxygen delivered by high-flow nasal cannula, noninvasive positive pressure ventilation, or clinical diagnosis of respiratory failure in setting of resource limitations), Septic shock (defined by SBP < 90 mm Hg, or Diastolic BP < 60 mm Hg), Multiple organ dysfunction/failure

WHAT EXACTLY ARE THOSE EXCLUSION CRITERIA?

THEY ARE EXCLUSIONS FROM BEING CONSIDERED SERIOUS.

What happened to those patients?

They were included as critical patients, as critical they were.

These are the inclusion criteria for CRITICAL ILLNESS. You know, the cohort for whom Leronlimab (the 16% slice) provided 82% reduction in mortality when administered (you know, day 0 and 7 with profound impact at day 14. p=0.023).

Oops, almost forgot. From https://clinicaltrials.gov/ct2/show/NCT04347239

Inclusion criteria:

Evidence of critical illness, defined by at least 1 of the following:
- Respiratory failure defined based on resource utilization requiring at least 1 of the following: Endotracheal intubation and mechanical ventilation, oxygen delivered by high-flow nasal cannula, noninvasive positive pressure ventilation, ECMO, or clinical diagnosis of respiratory failure (in setting of resource limitation)
OR
- Shock (defined by SBP < 90 mm Hg, or Diastolic BP < 60 mm Hg or requiring vasopressors)
OR
-Multiple organ dysfunction/failure

Thanks for the opportunity to set the record straight.